论文部分内容阅读
真菌感染的发病率随敏感人群的增加而增加。世界抗真菌药物市场每年增长20％,估计年销售额约20亿美元。最近氟康唑(fluconazole)年销售额2亿多美元,居首位,估计1991年销售额为4亿美元,且还有进一步增加的趋势。伊曲康唑(itraconazole)年销售额超过1亿美元。本文评价制药工业中几种抗真菌新药的现状和其优、缺点,以及5～10年内的可能趋势。市场情况 1990年全世界抗真菌药物销售额占药品总销售额的1.2％(20亿美元),或为抗感染
The incidence of fungal infections increases with increased susceptibility. The world market for antifungal drugs is up 20% annually, with an estimated annual sales of about 2 billion U.S. dollars. Fluconazole recently topped the list with annual sales of more than 200 million U.S. dollars and estimated 1991 sales of 400 million U.S. dollars, with further increases. Itraconazole annual sales of more than 100 million US dollars. This article evaluates the current status, advantages and disadvantages of several antifungal new drugs in the pharmaceutical industry, and the possible trends in 5-10 years. Market conditions Anti-fungal drug sales worldwide accounted for 1.2% of total drug sales ($ 2 billion) in 1990 or as anti-infectives